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A ratio of the vancomycin area under the concentration-time curve to the MIC (AUC/MIC) of>400 has been associated with
clinical success when treating Staphylococcus aureus pneumonia, and this target was recommended by recently published vanco-
mycin therapeutic monitoring consensus guidelines for treating all serious S. aureus infections. Here, vancomycin serum trough
levels and vancomycin AUC/MIC were evaluated in a “real-world” context by following a cohort of 182 patients with S. aureus
bacteremia (SAB) and analyzing these parameters within the critical first 96 h of vancomycin therapy. The median vancomycin
trough level at this time point was 19.5 mg/liter. There was a significant difference in vancomycin AUC/MIC when using broth
microdilution (BMD) compared with Etest MIC (medians of 436.1 and 271.5, respectively; P< 0.001). Obtaining the recom-
mended vancomycin target AUC/MIC of>400 using BMD was not associated with lower 30-day all-cause or attributable mortal-
ity from SAB (P 0.132 and P 0.273, respectively). However, an alternative vancomycin AUC/MIC of>373, derived using
classification and regression tree analysis, was associated with reduced mortality (P 0.043) and remained significant in a mul-
tivariable model. This study demonstrated that we obtained vancomycin trough levels in the target therapeutic range early dur-
ing the course of therapy and that obtaining a higher vancomycin AUC/MIC (in this case,>373) within 96 h was associated with
reduced mortality. The MIC test method has a significant impact on vancomycin AUC/MIC estimation. Clinicians should be
aware that the current target AUC/MIC of>400 was derived using the reference BMD method, so adjustments to this target
need to be made when calculating AUC/MIC ratio using other MIC testing methods.
There are growing concerns about the ongoing utility of vanco-mycin in the treatment of serious Staphylococcus aureus infec-
tions due to increasing reports of suboptimal outcomes (1, 2).
While fully vancomycin-resistant S. aureus (VRSA) remains rare
(3), infections caused by vancomycin-intermediate S. aureus
(VISA) and heterogeneous VISA (hVISA) may respond slowly or
incompletely to vancomycin (4, 5). Recently, new concerns have
been raised about suboptimal responses to vancomycin if theMIC
of the infecting organism lies at the upper end of the susceptible
range (6, 7), but this observation is not universal (8, 9).
The pharmacodynamic parameter that is thought to best pre-
dict vancomycin efficacy is the ratio of the 24-hour area under the
concentration-time curve to MIC (here referred to as AUC/MIC)
(10–13). Recently, consensus guidelines were published in the
United States to assist clinicians and pharmacists regarding van-
comycin dosing strategies (14). By attempting to bring consis-
tency to therapeutic monitoring using the current state of knowl-
edge about vancomycin pharmacodynamics and in view of
potential problems of efficacy, relative resistance, and toxicity,
these monitoring guidelines are intended to improve patient out-
comes. These guidelines recommend a vancomycin target AUC/
MIC of 400 (14) but also note that this target attainment is
difficult for isolates with vancomycin MICs of 1 mg/liter, and
they go on to suggest that alternate agents may be required for
therapy for infections with high vancomycin MICs (14–20).
The serum AUC/MIC target value of400 (using the 24-hour
AUC) was originally derived byMoise et al. (21) in a retrospective
study ofmethicillin-susceptible S. aureus (MSSA) andmethicillin-
resistant S. aureus (MRSA) hospital-acquired pneumonia using
classification and regression tree (CART) analysis. The investiga-
tors showed that an AUC/MIC of 345 predicted clinical cure,
while a value of 866 predicted bacterial eradication from the
lower respiratory tract. This study used a formula to estimateAUC
that they validated separately in adults (22). The published AUC
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formula, i.e., AUC  total vancomycin dose in mg over 24
h/{[(CLCR 0.79) 15.4] 0.06} (22), used the total daily dose
of vancomycin divided by the renal creatinine clearance (CLCR)
calculated according to the Cockcroft-Gault equation (23). The
MIC was measured using the Clinical and Laboratory Standards
Institute (CLSI) reference broth microdilution (BMD) method,
and the AUC/MIC was reported using the average AUC/MIC cal-
culated daily.
The consensus guidelines do not state whether the method of
CLCR estimation for AUC or MIC determination has any impact
on the calculatedAUC/MIC andwhether anAUC/MICof400 is
applicable to other S. aureus infection syndromes and outcome
measures, especially in a “real-world” clinical setting. We have
recently investigated outcomes in amulticenter cohort of S. aureus
bacteremia (SAB) patients and also have demonstrated an associ-
ation between increasing vancomycinMIC and increasedmortal-
ity. However, surprisingly, we found an association between in-
creased mortality and high vancomycin MIC whether or not
vancomycin was used for treatment (9), which may mean that a
high vancomycinMIC is amarker of some other patient or organ-
ism factor that is causally responsible for increased mortality. In
this new study, we sought to evaluate the impact of different van-
comycin MIC determination methods on AUC/MIC calculations
and to determine if achieving a vancomycin AUC/MIC of 400
was associated with improved outcomes in patients from this co-
hort treated with vancomycin for SAB.
(This work was presented in part at the 51st Interscience Con-
ference on Antimicrobial Agents and Chemotherapy, Chicago, IL,
2011, abstr. A-1681 [46].)
MATERIALS AND METHODS
Study population. Patients for this observational study were vancomy-
cin-treated patients from a previously described cohort (9). Patients
younger than 12 years were excluded from this pharmacodynamic analy-
sis because the formula we used to estimate vancomycin AUC has been
validated only in adults. The primary outcome measure was 30-day all-
cause mortality from the date of the first positive blood culture. Attribut-
able 30-day mortality was also evaluated using previously published cri-
teria (24). Other endpoints assessed included persistent bacteremia
(positive blood cultures at7 days after the initial isolate) and recurrence
of bacteremia within 30 days of the index positive blood culture (with
documented negative blood cultures after the index positive blood cul-
ture). Duration of bacteremia was measured as the number of days from
the index positive blood culture to the last positive blood culture ob-
tained.
Data collection. Data for age, sex, onset of bacteremia, antibiotic
treatment, and focus of S. aureus bacteremia infection were collected pro-
spectively. However, additional clinical data required for this analysis
were collected retrospectively using a detailed chart review. These in-
cluded renal function, admission to an intensive care unit (ICU), Acute
Physiology andChronicHealth Evaluation (APACHE) II score (25), Sim-
plified Acute Physiology Score (SAPS) II (26), Charlsonweighted index of
comorbidity (CWI) (27), Pitt bacteremia score (28), vancomycin dosing
regimens during the first 28 days of treatment, and serum vancomycin
levels. Illness severity scores were calculated as the worst values within 48
h prior to the onset of SAB (measured as the time of collection of the index
positive blood culture) (29). The following comorbidities were also col-
lected: heart disease (ischemic heart disease, congestive cardiac failure, or
cardiac arrhythmia requiring implantable electronic device), diabetes
mellitus, dialysis (established peritoneal or hemodialysis), malignancy
(solid organ or hematologic), transplant (solid organ or hematologic),
immunosuppression (receipt of chemotherapy, monoclonal antibody,
immunomodulation, or corticosteroids equivalent to prednisolone at 20
mg or more per day in the 30 days prior to SAB onset), liver disease
(chronic liver disease or cirrhosis), dementia, and active injecting drug use
(IDU). Contemporaneous local dosing guidelines recommended initial
dosing of vancomycin at 25 mg/kg every 12 h in adult patients with nor-
mal renal function (30) with subsequent dose adjustment according to
vancomycin serum trough levels, although individual regimens were ul-
timately decided by treating physicians. Compliance with these recom-
mendations was not assessed. As this was an observational study, vanco-
mycin levels were determined at the discretion of treating physicians.
Trough levels (or spot levels for patients on hemodialysis) were generally
obtained 24 to 96 h after commencement of vancomycin. Target trough
levels according to local guidelines (30) were 10 to 20 mg/liter, although
there was variability in recommended targets at different institutions;
modifications of vancomycin dosesweremade by individual treating phy-
sicians. The number of vancomycin levels obtained for each patient dur-
ing treatment varied according to the number of dose adjustments, fluc-
tuating renal function, alteration in clinical status, or at the judgment of
treating clinicians.
Microbiological data. The first positive blood culture isolate from
each patient was stored at80°C until undergoing detailed microbiolog-
ical testing. This included vancomycin MIC determination using BMD
(31) and Etest (bioMérieux, Marcy l’Etoile, France). Screening for hVISA
was performed using the Glycopeptide Resistance Detection (GRD) Etest
(bioMérieux, Marcy l’Etoile, France).
Vancomycin pharmacodynamic data. Renal function was estimated
using two commonly used formulae: the “175” Modification of Diet in
Renal Disease (MDRD) formula, which is an isotope dilution mass spec-
trometry (IDMS)-aligned equation that provides an estimated glomerular
filtration rate (eGFR), i.e., MDRD CLCR  175  [(CR in mol/liter 
0.0113)1.154]  [(age in years)0.203]  0.742 if female (32), and the
Cockcroft-Gault equation, which provides an estimated creatinine clear-
ance (CLCR), i.e., Cockcroft-Gault CLCR  {[(140  age in years) 
weight in kg]/(CR in mol/liter 0.814)} 0.85 if female, where weight
was calculated using actual body weight (23). There is no correction for
African-American race in theMDRD equation used in Australia andNew
Zealand, reflecting the low prevalence of this group in the Australasian
population (33). The MDRD eGFR is automatically reported alongside
serum creatinine results in most Australasian laboratories. The 24-hour
vancomycin AUC was calculated using the formula AUC total vanco-
mycin dose inmgover 24 h/{[(CLCR 0.79) 15.4] 0.06} andhas been
employed by other authors (34, 35). Timely achievement of therapeutic
serum vancomycin levels is critical in the treatment of bacteremia, so we
specifically evaluated the vancomycin AUC within the first 96 h of treat-
ment. The total vancomycin daily dose over 24 h used in the formula
corresponded to the vancomycin dose at the time of first available vanco-
mycin trough level for each patient, taken within 96 h of vancomycin
commencement. Actual body weight (where available) was used for the
Cockcroft-Gault equation. The AUC/MICwas calculated using bothMIC
methods.
Statistical analysis. The relationship between AUC/MIC and 30-day
mortality was explored both as a categorical variable and as a continuous
variable. For categorical analysis, both a two-group analysis and a three-
group analysis were performed using classification and regression tree
(CART) analysis to account for potential nonlinearity and nonmonoto-
nicity, respectively. For continuous univariable analysis, the AUC/MIC
was fitted by nonlinear regression to a standard exposure-response (Hill)
curve. Multivariable logistic regression was performed to identify factors
associated with 30-daymortality and to test the strength of the association
between AUC/MIC and outcome. The recommended target AUC/MIC
(400) and the CART-derived two-group AUC/MIC cutoff (Academic
CART Pro v6.6; Salford Systems, San Diego, CA) were both used to create
a dichotomous AUC/MIC variable for multivariable regression. Similarly
for multivariable analysis, continuous data such as age and disease or
illness severity markers were converted into dichotomous variables for
logistic regression using cutoffs associated with poor clinical outcomes
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frompreviously published studies. The2 test or Fisher exact test was used
to compare categorical variables, and theMann-Whitney test was used for
continuous nonparametric variables. Kaplan-Meier survival curves were
constructed, and the log rank test was used to compare the curves. Mul-
tivariable logistic regression was performed to identify factors associated
with 30-day mortality, with goodness of fit of the final model evaluated
with the Hosmer-Lemeshow statistic. Analyses were performed using
GraphPad Prism v5.0 (GraphPad Software, San Diego, CA), Stata v11.1
(StataCorp, College Station, TX), and R v2.15.2 (http://www.r-project
.org/).
Ethics. Human ethics committee approval was obtained at each of the
participating sites.
RESULTS
Demographics. Clinical and drug dosing data were available for
186 vancomycin-treated patients from our original cohort. Four
of these patients were excluded (1 patient, 30-day outcome not
recorded; 3 patients, 12 years), leaving 182 patients for final
analysis. Table 1 shows patient demographics according to 30-day
TABLE 1 Patient demographics according to 30-day outcome and vancomycin AUC/MIC (n 182)a
Characteristic
Value for groupb
30-day outcome Vancomycin AUC/MIC
Survivors (n 144) Nonsurvivors (n 38) P value 400 (n 83) 400 (n 99) P value
Age 70 yr 48 (33.3) 22 (57.9) 0.008 25 (30.1) 45 (45.5) 0.046
Male sex 105 (72.9) 23 (60.5) 0.163 62 (74.7) 66 (66.7) 0.258
White ethnicity 123 (85.4) 30 (79.0) 0.328 68 (81.9) 85 (85.9) 0.544
Hospital onset 71 (49.3) 21 (55.3) 0.586 46 (55.4) 46 (46.5) 0.238
MRSA 109 (75.7) 32 (84.2) 0.382 64 (77.1) 77 (77.8) 1.000
Device associatedc 72/135 (53.3) 17/36 (47.2) 0.575 42/76 (55.3) 47/95 (49.5) 0.538
Line associatedd 43/134 (32.1) 14/36 (38.9) 0.435 29/75 (38.7) 28/95 (29.5) 0.253
Infection syndrome
Skin and soft tissue 18 (12.5) 2 (5.3) 0.256 8 (9.6) 12 (12.1) 0.641
Infective endocarditis 7 (4.7) 1 (2.6) 1.000 3 (3.6) 5 (5.1) 0.729
Pneumonia 9 (6.3) 5 (13.2) 0.174 6 (7.2) 8 (8.1) 1.000
Osteoarticular 11 (7.6) 3 (7.9) 1.000 9 (10.8) 5 (5.1) 0.170
Sepsis syndrome 14 (9.7) 9 (23.7) 0.029 12 (14.5) 11 (11.1) 0.511
Comorbidities
Heart disease 54 (37.5) 18 (47.4) 0.271 29 (34.9) 43 (43.4) 0.287
Diabetes 45 (31.3) 13 (34.2) 0.845 19 (22.9) 39 (39.4) 0.025
Dialysis 27 (18.8) 6 (15.8) 0.815 8 (9.6) 25 (25.3) 0.007
Malignancy 28 (19.4) 15 (39.5) 0.017 24 (28.9) 19 (19.2) 0.161
Transplant 11 (7.6) 0 (0.0) 0.124 5 (6.0) 6 (6.1) 1.000
Immunosuppression 25 (17.4) 1 (2.6) 0.019 11 (13.3) 15 (15.2) 0.832
Liver disease 17 (11.8) 5 (13.2) 0.784 11 (13.3) 11 (11.1) 0.820
Dementia 8 (5.6) 2 (5.3) 1.000 3 (3.6) 7 (7.1) 0.350
Active IDU 8 (5.6) 0 (0.0) 0.208 6 (7.2) 2 (2.0) 0.144
Severity-of-illness markers
APACHE II score 18 46 (31.9) 20 (52.6) 0.023 26 (31.3) 40 (40.4) 0.219
SAPS II 45 5 (3.5) 5 (13.2) 0.035 4 (4.8) 6 (6.1) 0.757
CWI 3 40 (27.8) 15 (39.5) 0.170 20 (24.1) 35 (35.4) 0.108
Pitt bacteremia score 4 24 (16.7) 17 (44.7) 0.001 22 (26.5) 29 (19.2) 0.286
ICU admissionc 37/141 (26.2) 14/38 (36.8) 0.226 26/82 (31.7) 25/97 (25.8) 0.409
Acute renal failuree 33/143 (23.1) 11 (29.0) 0.524 18/83 (21.7) 26/98 (26.5) 0.490
Elevated vancomycin MICf 54 (37.5) 21 (55.3) 0.063 37 (44.6) 38 (38.4) 0.451
Vancomycin AUC/MIC 400 82 (56.9) 17 (44.7) 0.203
DNR order 19/121 (15.7) 28 (73.7) 0.001 20/74 (27.0) 27/85 (31.8) 0.602
30-day mortality 21 (25.3) 17 (17.2) 0.203
Persistent SABc 15/117 (12.8) 7/29 (24.1) 0.149 11/66 (16.7) 11/80 (13.8) 0.649
Recurrence of SABc 19/142 (13.4) 3/36 (8.3) 0.574 9/82 (11.0) 13/96 (13.5) 0.654
Duration of SAB, median days (IQR) 1 (1–2) 1.5 (1–5) 0.039 1 (1–2) 1 (1–2) 0.857
a Data exclude 1 patient for whom the 30-day outcome was unable to be confirmed and 3 pediatric patients of12 years. Abbreviations: AUC, area under the concentration-time
curve; MRSA, methicillin-resistant Staphylococcus aureus; IDR, injecting drug use; APACHE, Acute Physiology and Chronic Health Evaluation; SAPS, Simplified Acute Physiology
Score; CWI, Charlson weighted index of comorbidity; DNR, do not resuscitate; ICU, intensive care unit; IQR, interquartile range.
b Data are expressed as n (%) except as otherwise indicated.
c Information not available for all patients.
d Device-associated infection involving peripheral or central intravenous catheters only.
e Defined using assigned category for APACHE II calculation (25).
f Elevated vancomycin MIC defined as an Etest value of1.5 mg/liter.
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mortality and vancomycin AUC/MIC target attainment. The 30-
day all-cause mortality was 20.9% (38/182). Attributable mortal-
ity was 12.6% (23/182), indicating that more than one-third of all
deaths at 30 days (15/38, 39.5%) may have been due to causes
other than SAB. Nonsurvivors were more likely to be older, to
have a sepsis syndrome associated with SAB, to have a high van-
comycin MIC (defined as an Etest value of1.5 mg/liter) as pre-
viously described (9), and to have longer duration of bacteremia.
Patients achieving a vancomycin AUC/MIC of 400 were more
likely to be older and have diabetes or a requirement for perma-
nent dialysis. The median duration of bacteremia was 1 day
(range, 1 to 18 days), and rates of persistent or recurrent bactere-
mia in survivors and in nonsurvivors were similar. Documenta-
tion of patient weight was obtained for only 99 patients; in this
subset, themedianweightwas 71 kg (interquartile range [IQR], 61
to 90 kg), and there was no statistical difference between survivors
and nonsurvivors (P 0.673). Acute renal failure was present in
almost one-quarter of patients at onset of SAB.
Vancomycin trough levels. One or more vancomycin trough
levels were obtained for 165 patients (90.7%) within 96 h of com-
mencing treatment. The number of vancomycin levels per patient
obtained within this time period varied, mainly due to differences
in vancomycin dosing frequency. To account for these differences,
we evaluated those patients with vancomycin trough levels ob-
tained at 96 h after commencement (n  102), which approxi-
mates the earliest time of near steady state in a patient with normal
renal function receiving daily vancomycin dosing (before the
fourth dose). Themedian vancomycin trough at this timewas 19.5
mg/liter (interquartile range, 15.0 to 24.0 mg/liter). Table 2 shows
measured vancomycin trough levels at 96 h according to methi-
cillin susceptibility, vancomycin MIC, and 30-day outcome.
Vancomycin susceptibility. The distribution of vancomycin
MICs of the isolates determined by both Etest and BMD is shown
in Table 3 and demonstrates important differences in MIC be-
tween the two methods. The modal MIC was 1 mg/liter by BMD
(78.6%) and 1.5mg/liter by Etest (41.2%). Others have also noted
higher MIC values with Etest than with BMD (36–39). All isolates
were considered susceptible according to the CLSI reference BMD
method (31), but one isolate (0.6%) demonstrated vancomycin
heteroresistance using the Etest GRD.
Effect of CLCR calculation on vancomycin AUC. The eGFR
obtained using the MDRD formula was reported for all 182 pa-
tients; however, the estimatedCLCR obtained using theCockcroft-
Gault equation was calculated for only the 99 patients for whom
weight was documented. The MDRD formula tended to yield
higher values of CLCR (median, 50.6; IQR, 23.7 to 81.3) than the
Cockcroft-Gault equation (median 34.3, IQR 18.2 to 92.2); how-
ever, the difference in medians was not statistically significant
(P  0.468). The calculated vancomycin AUCs using both these
CLCR estimates were similar (MDRD median, 416.2; Cockcroft-
Gault median, 428.0; P 0.850).
Effect of MIC test method on vancomycin AUC/MIC. The
vancomycin AUC/MIC was calculated using the MDRD and
Cockcroft-Gault formulae for CLCR and BMD and Etest for MIC
(see Table S1 in the supplemental material). As there was no sig-
nificant difference in AUC calculation using either the MDRD
formula or the Cockcroft-Gault equation, we chose to use the
MDRD formula for CLCR as more data points were available for
further analysis. Themedian vancomycinAUC/MICwas different
using BMD and Etest (BMDmedian, 436.1 [IQR, 308.7 to 650.2];
Etest median, 271.5 [IQR, 189.1 to 376.6] [see Table S1 in the
supplemental material]). The very high AUC/MIC was calculated
in one patient with chronic kidney disease (serum creatinine, 447
mol/liter) whose blood culture isolate had a very low vancomy-
cin MIC (0.25 mg/liter). The calculated vancomycin AUC/MIC
was significantly higher when using the BMD MIC than with the
Etest MIC (P 0.001).
Figure 1 shows a scattergram of log-transformed vancomycin
AUC/MIC using BMD versus Etest. This demonstrates that there
is a clear difference in AUC/MIC values according toMICmethod
and that the target AUC/MIC of400 isMICmethod dependent.
Using a line of best fit derived by linear regression, the equivalent
AUC/MICusing theMICobserved byBMDof 400 is 226 using the
MIC observed by Etest in our cohort.
Effect of target AUC/MIC attainment on mortality in pa-
tients with SAB. Figure 2 displays the frequency distribution of
vancomycinAUC/MICwithin 96 h according to the proportion of
survivors. Using linear regression to create a line of best fit, there
was a positive but small correlation between vancomycin AUC/
MIC and mortality. Apart from the low proportion of survivors
with a vancomycin AUC/MIC of100, there was no clear demar-
cation of a specific vancomycin AUC/MIC associated with signif-
icant improvement of survival (r2 0.216, P 0.175). Figure 3A
TABLE 2 Vancomycin trough levels measured at 96 h after
commencing treatment (n 102)a
Characteristic (n)
Median vancomycin trough
level, mg/liter (IQR) P value
Susceptibility 0.784
MSSA (15) 17 (15–23)
MRSA (87) 20 (15–24)
Vancomycin MIC 0.323
Low (59) 19 (15–23)
Elevatedb (43) 21 (15–27)
30-day mortality 0.729
Survivors (85) 19 (15–23)
Nonsurvivors (17) 21 (16–26)
a Excludes 80 patients for whom the vancomycin trough level was drawn at other time
periods or not drawn at all. Abbreviations: IQR, interquartile range; MSSA, methicillin-
susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus.
b Elevated vancomycin MIC defined as an Etest value of1.5 mg/liter.
TABLE 3 Comparative vancomycin MIC distribution according to Etest
and BMD (n 182)a
Etest MIC
(mg/liter)
No. of isolates with BMDMIC
(mg/liter) of:
Total no. of
isolates0.25 0.5 1 2
0.38 1 1
0.5 1 1
0.75 5 2 7
1 9 14 23
1.5 9 64 2 75
2 1 52 5 58
3 11 6 17
Total no. of isolates 1 25 143 13 182
a BMD, broth microdilution.
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shows the vancomycin AUC/MIC from each patient according to
survivors versus nonsurvivors. The distributions of values around
the target vancomycin AUC/MIC of 400 using BMD are similar in
survivors and nonsurvivors (P  0.296), with a significant num-
ber of survivors (62/144, 43.1%) failing to achieve this target. The
proportion of survivors with a vancomycin AUC/MIC of 400
using BMD did not change if patients with peripheral or central
intravenous catheter-associated infection were excluded (37/91,
40.7%), and there was a similar proportion of survivors failing to
achieve a vancomycin AUC/MIC ratio of 226 using Etest (47/144,
32.60%).
Patients were then divided into two groups according to
whether they achieved the published target vancomycin AUC/
MIC of 400 using BMD MIC values (14, 22). Figure 3B shows
the proportion of survivors according to attainment or failure to
achieve the target vancomycin AUC/MIC of400, and there was
no significant difference between the two groups (P 0.203). The
Kaplan-Meier survival curve for 30-day all-cause mortality
(Fig. 3C) shows an early small divergence in the curves; however,
there was no statistical difference in survival (log rank test, P 
0.132) in patients who did not achieve the pharmacodynamic tar-
get vancomycin AUC/MIC of 400 using BMD MIC compared
with thosewhodid. In addition, therewas nodifference in survival
when analyzing according to 30-day attributable mortality (P 
0.273) or adjusting for methicillin susceptibility (see Table S2 in
the supplemental material).
Using CART, a breakpoint for 30-day all-causemortality using
BMD was identified for the vancomycin AUC/MIC at 373. The
probability of survival was 71.6% for those with a vancomycin
AUC/MIC of373, compared with 84.3% for those patients with
a vancomycin AUC/MIC of373. There was a statistically signif-
icant difference in all-cause mortality using this CART-derived
vancomycin AUC/MIC (P  0.043). Using the mortality differ-
ence between these two groups as a point estimate for absolute risk
reduction (12.7%), the number needed to treat was 8 (compared
with 14 for the predefined vancomycin AUC/MIC cutoff of 400).
There were nomajor differences in baseline patient demographics
according to the CART-derived vancomycin AUC/MIC target of
373 compared with those reported in Table 1 for the target of 400
(see Table S3 in the supplemental material). Figure 3D demon-
strates the proportion of survivors according to attainment of the
CART-derived vancomycin AUC/MIC of373 (P 0.043), and
Fig. 3E shows the Kaplan-Meier survival curve using the CART-
derived target (log rank test, P 0.043). Among survivors, there
was still a significant proportion (53/144, 36.8%) who failed to
achieve a vancomycin AUC/MIC of 373. There was no differ-
ence in mortality when adjusted for methicillin susceptibility (see
Table S4 in the supplemental material). The CART-derived cutoff
for Etest was 130 (P 0.005 for 30-day all-cause mortality).
We also analyzed the vancomycin AUC/MIC using BMD ac-
cording to vancomycin MIC group, given our previously demon-
strated association between elevated vancomycinMIC and 30-day
mortality. Figure 4 shows a dot plot of vancomycin AUC/MIC
FIG 1 Scattergram of vancomycin AUC/MIC using BMD versus Etest. The
vertical dotted line represents an AUC/MIC of 400 using BMD. The horizontal
dotted line represents an AUC/MIC of 226 using Etest. The line of best fit was
obtained using linear regression. BMD, brothmicrodilution; AUC/MIC, ratio
of area under the concentration-time curve (24 h) to vancomycin MIC.
FIG 2 Frequency distribution of vancomycin AUC/MIC according to the proportion of survivors, including line of best fit using linear regression. AUC/MIC,
ratio of area under the concentration-time curve (24 hour) to vancomycin MIC; BMD, broth microdilution.
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according to low versus elevated vancomycin MIC (Etest, 1.5
mg/liter). As expected, the AUC/MICwas lower in the group with
elevated vancomycinMIC. However, when analyzed according to
target attainment of anAUC/MICof400 usingBMDMIC, there
was no statistical difference between the groups with low and ele-
vated vancomycin MIC (61/107 [57.0%] versus 38/75 [50.7%],
respectively; P  0.451) or between MSSA and MRSA (22/41
[53.7%] versus 77/141 [54.6%], respectively; P  1.000). When
using the CART-derived AUC/MIC target of 373, there were
also no statistical differences between these two groups (low ver-
sus elevated vancomycin MIC, P  0.880; MSSA versus MRSA,
P 1.000).
FIG 3 Thirty-day mortality in patients with SAB according to vancomycin AUC/MIC. (A) Vancomycin AUC/MIC according to survivors versus nonsurvivors
for all-causemortality. (B) Proportion of survivors according to target attainment using a vancomycin AUC/MIC of400. (C) Kaplan-Meier curve for all-cause
mortality according to target attainment using a vancomycin AUC/MIC of400 (note that the P value derived using the log-rank test was slightly different to
Fisher’s exact test for the dichotomous variable). (D) Proportion of survivors according to target attainment using a vancomycin AUC/MIC of 373. (E)
Kaplan-Meier curve for all-cause mortality according to target attainment using a vancomycin AUC/MIC of 373. The horizontal dotted line represents an
AUC/MIC of 400 using BMD. Heavy black bars represent median and interquartile range. BMD, broth microdilution; AUC/MIC, ratio of area under the
concentration-time curve (24 hour) to vancomycin MIC.
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We found no association between achieving a vancomycin AUC/
MICof400 (published target) or373 (ourCART-derived target)
and reduction in other secondary outcome measures such as attrib-
utable mortality (400, P  0.273; 373, P  0.115), persistent
bacteremia (400, P 0.649;373, P 1.000), or recurrent bacte-
remia (400, P  0.654; 373, P  0.817). Among nonsurvivors,
the proportions of patients achieving a vancomycin AUC/MIC of
400 in attributable versus nonattributable deaths were similar
(10/23 versus 7/15, respectively; P 1.000).We also analyzed differ-
ent target AUC/MIC cutoffs reported in various studies (AUC/
MICBMDof345 [21], AUC/MICBMDof866 for bacterial eradica-
tion [21], AUC/MICEtest of211 [40], and AUC/MICBMD of421
[41])and foundnostatisticaldifference in30-dayoutcomeaccording
to achievement of these targets.
Relationship between vancomycin trough level and vanco-
mycin AUC. As the formula used to calculate vancomycin AUC,
i.e., AUC  total vancomycin dose in mg over 24h/{[(CLCR 
0.79)  15.4]  0.06}, did not include measured vancomycin
trough levels from patients, we also assessed the relationship be-
tween vancomycin trough levels measured within 96 h of treat-
ment commencement and vancomycin AUC. There was only a
moderate correlation between measured vancomycin trough lev-
els and calculated vancomycin AUC (r 0.246, P 0.002).
Multivariable analysis. Variables identified as potentially sig-
nificant on univariable analysis (P  0.2) were considered for
inclusion into a multivariable model to establish risk factors for
30-day mortality. For correlated variables (for example, age and
APACHE II score), only one was included in multivariable analy-
sis. Do-not-resuscitate (DNR) orders were specifically excluded
from this model as these lead to modifications or withdrawal of
treatment that have a direct impact on clinical outcome. Using
multivariable logistic regression, variables that were indepen-
dently associated with increased 30-daymortality in SABwere age
of70 years, sepsis syndrome, and a Pitt bacteremia score of4,
whereas a vancomycin AUC/MIC of 373 was protective
(Table 4) (Hosmer-Lemeshow statistic for final model, P 
0.089).
DISCUSSION
There is an accepted association between poorer outcomes in S.
aureus infections and an elevated vancomycin MIC within the
susceptible range (6), leading some to question the ongoing value
of vancomycin in the treatment of serious S. aureus infections (1).
Higher vancomycin doses have been recommended to optimize
outcomes but at the price of increased nephrotoxicity (42). The
most precise pharmacodynamic predictor of outcome is thought
to be the vancomycin AUC/MIC, and it is considered to be more
accurate than related measures such as time above MIC and the
peak/MIC ratio in in vitro, animal, and small human studies (10–
13, 22). Acknowledging that comprehensive clinical data are lack-
ing, consensus guidelines (14) for vancomycin dosing and moni-
toring recommend a number of strategies intended to optimize
outcomes, minimize toxicity, and prevent the development of re-
sistance. Key recommendations are to achieve vancomycin serum
trough levels of 15 to 20 mg/liter and an AUC/MIC of400. This
ratio was originally derived from patients with staphylococcal
pneumonia, using the BMDmethod forMIC determination and a
formula based on vancomycin dosing and CLCR for AUC (21, 22)
and evaluating clinical success. In this study, we evaluated the
usefulness of the AUC/MIC of400 in patients with staphylococ-
cal bacteremia.We also assessed the impact of two differentmeth-
ods of MIC determination on AUC/MIC calculations and then
sought to determine if achieving a vancomycin AUC/MIC of
400 with the BMDmethod within the first critical 96 h of ther-
apy resulted in reducedmortality in our cohort of patients with S.
aureus bacteremia.
Not surprisingly we found that calculation of the vancomycin
AUC/MIC is MIC method dependent, so clinicians need to be
aware of this and specify the methods used to obtain MIC values
when aiming for particular AUC/MIC targets. An Etest MIC is
often higher than that with the BMDmethodology (9, 36–38, 43).
TABLE 4 Final multivariable logistic regression model of factors
associated with 30-day mortality in SAB (n 182)a
Variableb
Univariable
analysis
P value
Multivariable analysis
OR 95% CI P value
Age 70 years 0.008 3.61 1.59–8.17 0.002
Male sex 0.163
Pneumonia 0.174
Sepsis syndrome 0.029 3.24 1.16–9.08 0.025
Vancomycin AUC/MIC 373 0.043 0.44 0.20–0.99 0.049
Elevated vancomycin MICc 0.063
CWI 3 0.170
Pitt bacteremia score 4 0.001 3.74 1.64–8.56 0.002
Immunosuppression 0.019
a Abbreviations: OR, odds ratio; CI, confidence interval; AUC, area under the
concentration-time curve; DNR, do not resuscitate; APACHE, Acute Physiology and
Chronic Health Evaluation; SAPS, Simplified Acute Physiology Score; CWI, Charlson
weighted index of comorbidity.
b Variables that were significant on univariable analysis that were not considered for
multivariable analysis were presence of DNR order (direct effect on outcome), an
APACHE II score of18, a SAPS II of45, and heart disease and malignancy
(collinearity).
c Elevated vancomycin MIC defined as an Etest value of1.5 mg/liter.
FIG 4 Vancomycin AUC/MIC according to groups with low versus elevated
(defined as an Etest value of1.5 mg/liter) vancomycin MIC. The horizontal
dotted line represents an AUC/MIC of 400 using BMD. Heavy black bars
represent median and interquartile range. BMD, broth microdilution; AUC/
MIC, ratio of area under the concentration-time curve (24 hour) to vancomy-
cin MIC.
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We suspect that this is the result of an inoculum effect (the inoc-
ulum is higher with Etest), which has been observed in vivo (44).
As a result, the vancomycin AUC/MIC is significantly lower when
using Etest MIC than when using the BMD MIC. If the Etest is
used to measure MIC, then we have calculated that the equivalent
AUC/MIC target should be 226 rather than 400 using our linear
regression model. Vancomycin AUCmeasurement may also vary
according to the method used for its estimation. Although the
MDRD formula was developed as a tool for evaluation of chronic
kidney disease and may underestimate renal clearance in healthy
individuals (45), we showed that differences in CLCR calculation
using the MDRD and Cockcroft-Gault formulae have little influ-
ence on vancomycin AUC estimates using the formula published
by Moise-Broder et al. (22).
With these caveats in mind, we then investigated the prognos-
tic value of the recommended vancomycin AUC/MIC of400 as
determined by BMD in our cohort of patients with S. aureus bac-
teremia in a “real-world” setting. Target vancomycin trough levels
were achieved early in the vancomycin treatment course (within
96 h), potentially maximizing vancomycin efficacy. While there
was a gradual rise in the proportion of survivors as the vancomy-
cin AUC/MIC increased, there was no clear cutoff associated with
improved survival (Fig. 2 and Fig. 3A). The a priori defined van-
comycin AUC/MIC of400 obtained within 96 h of therapy was
associated with a calculated 8% reduction in mortality, but this
was not a statistically useful predictor of outcome.However, when
we moved away from an a priori definition and used CART anal-
ysis to establish a new AUC/MIC cutoff, we did find a statistically
significant association between achieving a vancomycin AUC/
MIC of 373 within the first 96 h of vancomycin therapy and
reduced 30-day mortality. Patients who achieved an AUC/MIC of
373 had a 12% lower mortality than those who did not (P 
0.04). The CART-derived value is in fact closer to the original
vancomycin AUC/MIC of 345 reported byMoise et al. (21), upon
which the target of 400 was established. While it makes biological
and clinical sense that higher vancomycin AUC/MIC ratios di-
rectly improve patient outcomes, we caution that the relationship
may bemore complex than this, particularly as our previous study
(9) demonstrated that a high vancomycin MIC was associated
with increased mortality even in patients who were not treated
with vancomycin. We believe that multiple factors apart from the
vancomycin AUC/MIC influence outcome, including strain-spe-
cific genotypic and virulence differences and the host-organism
interaction. Even using the new cutoff of 373 that we obtained
with CART, almost 90% of the survival difference between pa-
tients is likely to be explained by factors other than the AUC/MIC
itself.
Other studies have examined vancomycin AUC or AUC/MIC
but they describe a variety of different infection syndromes and
outcome measures. In their original paper describing the vanco-
mycin AUC/MIC, Moise et al. (21) evaluated 70 patients with
hospital-acquired pneumonia (principally ventilator associated)
due to MSSA and MRSA. The Cockcroft-Gault CLCR and the ref-
erenceMIC BMDmethod were used to calculate their AUC/MIC.
Other studies, including this one, have evaluated patients with
staphylococcal bacteremia. Neuner et al. (35) investigated vanco-
mycin the AUC/MIC as a predictor of persistent MRSA bactere-
mia in 222 patients. ThemedianAUC/MICusing Etest was similar
in the persistent versus nonpersistent bacteremia groups (325 and
283, respectively; P 0.936), although there were only 19 patients
with persistent bacteremia. Brown et al. (40) assessed 50 patients
with complicated bacteremia or infective endocarditis. A vanco-
mycin AUC/MIC of211 using Etest was associated with attrib-
utable mortality; however, only 8 patients (16%) had mortality
attributable to SAB. Interestingly our CART-derived cutoff for
30-day mortality and a vancomycin AUC/MIC obtained using
Etest instead of BMDwasmuch lower (130).More recently Kullar
et al. (41) studied 320 patients with MRSA bacteremia using a
composite endpoint of treatment failure (30-day mortality, per-
sistent symptoms and signs of infection, and persistent bacteremia
for7 days). Both BMD and EtestMIC determinations were per-
formed. Using CART analysis, an AUC/MIC of 421 (presum-
ably using BMD) was associated with treatment failure. Interest-
ingly, high rates of persistent bacteremia (127/168) were noted,
and the median AUC/MIC values with treatment success versus
failure were similar (587 and 537, respectively).
There are several limitations to our study. Information about
surgical debridement or removal of devices was not obtained, and
we were unable to ascertain compliance with local vancomycin
dosing guidelines or to assess rates of nephrotoxicity. Due to
widely varying dosage schedules, we did not account for expected
differences in trough levels depending on dosing frequency. The
vancomycin AUC was calculated with a simple formula based on
daily vancomycin dose and renal function; however, this does not
take into consideration the measured serum vancomycin levels
obtained frompatients. This is an acceptedmethod for AUC/MIC
estimation; however, more sophisticated computer-based pro-
grams may be able to improve AUC estimation. Our study also
included patients with a wide variety of infective processes associ-
ated with bacteremia, including a proportion that were likely to
have good outcomes, such as those with skin and skin structure
infection or line sepsis who had the device removed early. Never-
theless, our study suggests that refinements need to be made to
recommendations for AUC/MIC target attainment in treatment
of S. aureus bacteremia. The heterogeneous nature of our results
and those from other studies raises the suspicion that the relation-
ship between vancomycinAUC andMICmay be different accord-
ing to infection type or site and outcome measure. In particular
infections associated with high bacterial loads may be a particular
problem, as a true inoculum effect with vancomycin has been
demonstrated (44). Previous studies have evaluated the average
daily vancomycin AUC/MIC at steady state during a course of
vancomycin treatment (22, 40), whereas we have focused on as-
sessing the vancomycinAUC/MIC achievedwithin the first 96 h of
vancomycin therapy. We believe that this is a clinically relevant
endpoint and may provide clinicians with an alternative measure
of efficacy in addition to monitoring vancomycin trough levels
during the early stages of treatment for SAB.
The optimum vancomycin AUC/MIC using non-BMD MIC
methods has not been established. Therefore, clinicians using
pharmacodynamic targets to guide vancomycin therapy for seri-
ous S. aureus infections need to be alert to the method of MIC
determination in their own laboratories when calculating the van-
comycin AUC/MIC, as this will influence the numerical target.
Improved algorithms for AUC calculation that include actual
measured serum vancomycin levels may be beneficial. Further
research into the generalizability of AUC/MIC targets in different
S. aureus infection syndromes and outcomemeasures is required.
Appropriate vancomycin dosing to achieve serum trough levels
within the target therapeutic range early in the treatment course is
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also important, andmanagement should also take the clinical sta-
tus of the patient into consideration. Achieving a vancomycin
AUC/MIC that approximates the target of 400 rapidly during
the early treatment of SAB is associated with improved survival;
however, this effect is small, and survival is likely to be heavily
dependent on other, as-yet-unknown host and organism charac-
teristics.
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